Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP771814.RAI2QDjqwKYMsFS0no_Q45IbybgWKaB2EmaNq26AUIfCQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP771814.RAI2QDjqwKYMsFS0no_Q45IbybgWKaB2EmaNq26AUIfCQ130_assertion type Assertion NP771814.RAI2QDjqwKYMsFS0no_Q45IbybgWKaB2EmaNq26AUIfCQ130_head.
- NP771814.RAI2QDjqwKYMsFS0no_Q45IbybgWKaB2EmaNq26AUIfCQ130_assertion description "[The activation of this pathway explains the use of both VEGF and VEGF-receptor inhibitors (bevacizumab, sunitinib and sorafenib) in the therapy of advanced CCRCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP771814.RAI2QDjqwKYMsFS0no_Q45IbybgWKaB2EmaNq26AUIfCQ130_provenance.
- NP771814.RAI2QDjqwKYMsFS0no_Q45IbybgWKaB2EmaNq26AUIfCQ130_assertion evidence source_evidence_literature NP771814.RAI2QDjqwKYMsFS0no_Q45IbybgWKaB2EmaNq26AUIfCQ130_provenance.
- NP771814.RAI2QDjqwKYMsFS0no_Q45IbybgWKaB2EmaNq26AUIfCQ130_assertion SIO_000772 20437403 NP771814.RAI2QDjqwKYMsFS0no_Q45IbybgWKaB2EmaNq26AUIfCQ130_provenance.
- NP771814.RAI2QDjqwKYMsFS0no_Q45IbybgWKaB2EmaNq26AUIfCQ130_assertion wasDerivedFrom befree-20150227 NP771814.RAI2QDjqwKYMsFS0no_Q45IbybgWKaB2EmaNq26AUIfCQ130_provenance.
- NP771814.RAI2QDjqwKYMsFS0no_Q45IbybgWKaB2EmaNq26AUIfCQ130_assertion wasGeneratedBy ECO_0000203 NP771814.RAI2QDjqwKYMsFS0no_Q45IbybgWKaB2EmaNq26AUIfCQ130_provenance.